IGF-1 LR3 Research Guide: Mechanism, Studies & Reconstitution Protocol

IGF-1 LR3 (Insulin-like Growth Factor 1, Long R3) is a synthetic analog of human insulin-like growth factor 1 (IGF-1) engineered for extended biological activity. By substituting a single amino acid and adding a 13-residue N-terminal extension, researchers produced a compound that retains full IGF-1 receptor binding and signaling activity while dramatically extending plasma half-life. IGF-1 LR3 has become a standard research tool in studies of cellular proliferation, metabolism, muscle biology, and the GH-IGF axis.

For research use only. Not intended for human or veterinary use.

Background: The GH-IGF-1 Axis

Insulin-like growth factor 1 (IGF-1) is a 70-amino acid single-chain peptide hormone produced primarily by the liver in response to growth hormone (GH) stimulation. It circulates bound to a family of six IGF-binding proteins (IGFBPs 1–6), which regulate its bioavailability, tissue distribution, and half-life. Free IGF-1 — the biologically active fraction — binds to the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally homologous to the insulin receptor.

IGF-1 mediates the majority of GH’s anabolic and growth-promoting effects and exerts additional GH-independent actions in peripheral tissues. Key physiological roles include:

• Stimulation of skeletal muscle protein synthesis and satellite cell activation
• Promotion of linear bone growth via chondrocyte proliferation in growth plates
• Regulation of glucose metabolism (IGF-1R shares ~60% sequence homology with the insulin receptor and can activate insulin signaling pathways)
• Neuroprotective and neurotrophic effects in the CNS
• Anti-apoptotic signaling in multiple cell types

What Is IGF-1 LR3?

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of IGF-1 with two key structural modifications:

• Glu3 → Arg3 substitution: Replacement of glutamic acid at position 3 with arginine dramatically reduces binding affinity to IGFBPs (particularly IGFBP-3, the dominant carrier protein for circulating IGF-1), freeing a greater proportion of the molecule to interact with IGF-1R
• 13-amino acid N-terminal extension: Addition of a 13-residue extension (Met-Leu-Pro-Ala-Leu-Leu-Pro-Pro-Ala-Leu-Pro-Gln-Gly-) further reduces IGFBP binding and increases resistance to proteolytic degradation

The combined effect of these modifications produces a compound with:

• ~2–3 fold reduced IGFBP binding compared to native IGF-1, resulting in a greater free fraction
• Extended plasma half-life: approximately 20–30 hours vs. ~15 minutes for free native IGF-1
• Equivalent IGF-1R binding affinity and downstream signaling potency

Mechanism of Action

IGF-1R Binding and Downstream Signaling

IGF-1 LR3 binds to and activates the IGF-1R with affinity comparable to native IGF-1. IGF-1R is a heterotetrameric receptor consisting of two extracellular α-subunits and two transmembrane β-subunits linked by disulfide bonds. Ligand binding induces conformational changes that activate the intracellular tyrosine kinase domains of the β-subunits via autophosphorylation, initiating two major downstream signaling cascades:

• PI3K/Akt/mTOR pathway: Mediates the majority of IGF-1’s anabolic and anti-apoptotic effects; promotes protein synthesis via mTORC1, glucose uptake via GLUT4 translocation, and cell survival via phosphorylation of pro-apoptotic targets
• Ras/MAPK/ERK pathway: Primarily mediates mitogenic (proliferative) effects; drives cell cycle progression and differentiation responses

Insulin Receptor Cross-Reactivity

Due to structural homology between IGF-1R and the insulin receptor (IR), IGF-1 LR3 has measurable affinity for IR — approximately 1/500th of its IGF-1R affinity. At high concentrations used in some cell-based research applications, this cross-reactivity should be considered as a potential confound in metabolic studies. Hybrid receptors (IGF-1R/IR heterodimers) present in many cell types may also be activated, with signaling characteristics intermediate between the two receptors.

IGFBP Bypass

A critical aspect of IGF-1 LR3’s utility as a research tool is its reduced IGFBP binding. In normal physiology, greater than 99% of circulating IGF-1 is bound to IGFBPs — primarily IGFBP-3 in a ternary complex with ALS (acid-labile subunit). This extensive protein binding sequesters IGF-1, prolongs its half-life, and modulates its access to tissues and receptors. IGF-1 LR3’s low IGFBP affinity means it circulates predominantly in free, bioactive form, producing more direct and sustained IGF-1R stimulation than equivalent doses of native IGF-1.

Key Research Applications

Muscle Biology and Protein Synthesis

IGF-1 LR3 is extensively used in skeletal muscle research to study the IGF-1/Akt/mTOR signaling axis and its regulation of muscle protein synthesis, hypertrophy, and satellite cell function. Adams and McCue (1998) demonstrated that local IGF-1 overexpression in skeletal muscle activated satellite cells and promoted muscle fiber hypertrophy in rodent models. Subsequent work using IGF-1 LR3 as a tool compound has extended these findings, establishing the mTORC1 pathway as the central mediator of IGF-1-induced muscle anabolism and delineating the roles of specific downstream effectors (S6K1, 4E-BP1) in translational control of muscle protein synthesis.

Cell Culture and In Vitro Research

IGF-1 LR3 is widely used as a cell culture supplement in place of native IGF-1 or insulin due to its potency, stability, and reduced serum requirement. At nanomolar concentrations, it promotes cell survival, proliferation, and differentiation in primary cultures and cell lines — functions attributed to PI3K/Akt-mediated suppression of apoptosis and Ras/MAPK-driven mitogenesis. Its extended half-life in culture media (relative to native IGF-1, which is susceptible to proteolytic degradation) allows for reduced dosing frequency in long-term culture experiments.

Muscle Wasting and Cachexia Models

IGF-1 LR3 has been studied as a tool to counteract muscle atrophy in models of disuse, denervation, glucocorticoid-induced wasting, and cancer cachexia. Its extended activity profile makes it practical for repeated-dose animal studies without the rapid degradation that limits native IGF-1’s utility. Research has demonstrated that IGF-1 LR3 can attenuate atrophy-related gene expression programs (including upregulation of MuRF1 and MAFbx ubiquitin ligases) and preserve lean mass in catabolic rodent models.

Neuroprotection and CNS Research

IGF-1 signaling plays important neuroprotective roles in the CNS, and IGF-1 LR3 has been used in models of neuronal injury, ischemia, and neurodegenerative disease to study these pathways. IGF-1R activation promotes neuronal survival through PI3K/Akt-mediated inhibition of apoptosis and supports axonal growth, synaptogenesis, and myelination. Research in rodent stroke models has demonstrated that peripheral IGF-1 LR3 administration can cross the blood-brain barrier in sufficient quantities to reduce infarct volume and improve functional recovery.

IGF-1 LR3 vs. Native IGF-1: Research Considerations

Reconstitution Protocol

IGF-1 LR3 is supplied as a lyophilized powder requiring reconstitution before research use. Due to its tendency to adsorb to surfaces, careful technique is important.

• Reconstitute with bacteriostatic water (0.1–1% acetic acid solutions are sometimes preferred for initial dissolution, followed by dilution to working concentration in PBS with 0.1% BSA to prevent adsorption)
• Inject diluent slowly along the inner wall of the vial — do not inject directly onto the lyophilized cake
• Gently swirl until fully dissolved; do not vortex
• Typical working concentrations: 0.1–100 ng/mL for cell culture; higher for in vivo applications
• Aliquot to avoid repeated freeze-thaw cycles; store working aliquots at 2–8°C for up to 2 weeks
• Long-term storage: -80°C (preferred) or -20°C for lyophilized material; add carrier protein (0.1% BSA) to reconstituted solutions intended for storage

References

• Adams, G. R., & McCue, S. A. (1998). Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. Journal of Applied Physiology, 84(5), 1716–1722.
• Baserga, R. (1999). The IGF-I receptor in cancer research. Experimental Cell Research, 253(1), 1–6.
• Froesch, E. R., Schmid, C., Schwander, J., & Zapf, J. (1985). Actions of insulin-like growth factors. Annual Review of Physiology, 47, 443–467.
• Clemmons, D. R. (2007). Modifying IGF1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews Drug Discovery, 6(10), 821–833.
• Rinderknecht, E., & Humbel, R. E. (1978). The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry, 253(8), 2769–2776.
• Francis, G. L., Ross, M., Ballard, F. J., Milner, S. J., Bhala, A., Wallace, J. C., & Read, L. C. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213–223.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.